Seahorse Bioscience, Inc. Responds to Requests from Scientists in France, Appoints Proteigene Distributor
NORTH BILLERICA, Mass., Oct. 13 -- Seahorse Bioscience, Inc., the leader in the design and development of instruments for assessing cellular bioenergetics, today announced Proteigene as a supplier of Seahorse XF Analyzers and consumables in France. Seahorse Extracellular Flux Analyzers provide the first and only method to measure the two major energy producing pathways - mitochondrial respiration and glycolysis - in living cells in a microplate.
"France's contribution to research and drug discovery is well known, observed M. Philippe Dutriat, Director of Proteigene. "We have a large number of bioenergetic scientists who are looking for newer methods for studying mitochondrial dysfunction, and in particular its role in cancer, obesity and age-related diseases. Seahorse XF Analyzers offer the only practical and modern way to study mitochondria in whole cells."
Introduced in June of 2006, the XF Analyzer allows scientists to assess the impact of drugs, genetic modifications and environment by monitoring the rate that cells consume oxygen and produce metabolic byproducts including acid and carbon dioxide.
"The first publication containing Seahorse data appeared in Nature with data generated by Scientist Johan Auwerx of the Institut de Genetique et Biologie Moleculaire et Cellulaire in collaboration with Mitshurio Watanabe and Antonio Bianco of Harvard Medical School. Since then there have been a growing number of our prospects in France asking for a French distributor for Seahorse products to simplify their purchasing process," said Hasse Hedeby, Manager of European Sales for Seahorse. "We chose Proteigene as our agent in France after seeing their commitment to understanding and supporting their customers-something we believe strongly in."
About Seahorse Bioscience
SEAHORSE XF ANALYZERS have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit http://www.seahorsebio.com.
PROTEIGENE, founded in 1999, is promoting and supporting customers in France, Belgium, and Switzerland with robotic systems and consumables for obesity, diabetes, ageing, cancer, cardiovascular research. For more information, please visit www.proteigene.com or www.proteigenecell.com .
SOURCE Seahorse Bioscience, Inc.